申请人:Newron Pharmaceuticals S.p.A.
公开号:EP1870097A1
公开(公告)日:2007-12-26
The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an α-aminoamide, particularly safin amide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, Mild Cognitive Impairment (MCI) and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob diseases, multiple sclerosis (MS), other white matter disorders and drug-induced cognitive worsening.
本发明属于通过施用α-氨基酰胺,特别是沙芬酰胺,对学习和记忆中的认知障碍进行药物治疗的领域。本发明化合物可治疗的认知障碍包括自闭症、阅读障碍、注意缺陷多动障碍、精神分裂症、强迫症、精神病、双相情感障碍、抑郁症、抽动秽语综合征、轻度认知障碍(MCI)以及儿童、青少年和成人的学习障碍、青少年和成人的轻度认知障碍(MCI)和学习障碍、年龄相关性记忆障碍、年龄相关性认知衰退、阿尔茨海默病、帕金森病、唐氏综合症、脑外伤、亨廷顿氏病、进行性核上性麻痹(PSP)、艾滋病、中风、血管疾病、皮克氏病或克雅氏病、多发性硬化症(MS)、其他白质疾病以及药物引起的认知恶化。